Sanofi

Sanofi launches project to develop vaccine against Zika Virus

Sanofi launches project to develop vaccine against Zika Virus

Sanofi has come up with a project to create a vaccine against the Zika virus. The is the most decisive commitment so far by any leading vaccine producer to battle the disease associated with multiple birth defects in Brazil.

On Tuesday, the French drugmaker said that its Sanofi Pasteur vaccines division has decided to utilize its expertise in creating vaccines for similar viruses like yellow fever, Japanese encephalitis and, the dengue most recently.

The move has been taken a day after the World Health Organization (WHO) has declared the mosquito-borne Zika virus as an international public health emergency because of its association with underdeveloped brains in a number of babies.

Mexican Government nod for Sanofi to Market First Dengue Vaccine

Mexican Government nod for Sanofi to Market First Dengue Vaccine

The world may have a dengue vaccine soon as Sanofi Pasteur has received approval from the Mexican government to market the first ever dengue vaccine that can prevent the fastest growing mosquito-borne disease in the world today.

In a press release, Swiftwater vaccine maker Sanofi informed that its tetravalent dengue vaccine Dengvaxia is capable of helping patients with the mosquito-borne disease caused by all four dengue virus types. “In two studies, the vaccine reduced dengue from all four viral variations in two-thirds of the participants. It also showed that the vaccine prevented 9 out of 10 cases of severe dengue and 8 out 10 hospitalizations due to dengue in this age group”, as per the company.

Diabetes combination drug LixiLan hits goal in second late-stage trial

Diabetes combination drug LixiLan hits goal in second late-stage trial

On Monday, Sanofi said a second late-stage Phase III study of its LixiLan diabetes drug had met its key target. This success has made it all set for regulatory submissions by the fourth quarter in the United States and the first quarter of next year in the European Union.

LixiLan includes a single-injection combination of Lyxumia, a drug developed with Danish drugmaker Zealand Pharma, and Sanofi's Lantus. It is aimed at patients with type-2 diabetes.

In a statement, the French drugmaker said the full results will be communicated in a future scientific forum.

The French drugmaker said that the LixiLan-L Phase III clinical trial has achieved its primary endpoint in patients with type 2 diabetes, who went under treatment with insulin glargine with or without metformin.

Google, Sanofi join hands to improve Diabetes Management

Google, Sanofi join hands to improve Diabetes Management

Google Inc and French drugmaker Sanofi SA are going to join hands to develop tools for improving the management and treatment of diabetes. According to the International Diabetes Federation, Sanofi will work with Google's Life Sciences team for collecting, analyzing and understanding information that has impact on diabetes. It is likely to affect 592 million by 2035.

Sanofi's diabetes product line raked in sales of EUR 1.9 billion which is around Rs. 14,120 crores and will contribute about 20% to the company's total sales in the second quarter. The continued pricing pressure in the United States has hurt the sales in this strategic unit.

Sanofi Teams Up With Evotec and Apeiron to Develop New Immune System-Boosting Cancer Medicine

Sanofi Teams Up With Evotec and Apeiron to Develop New Immune System-Boosting

French multinational pharmaceutical company Sanofi said that it is joining hand with Germany’s Evotec and Austrian biotech firm Apeiron Biologics to develop a new immune system-boosting cancer medicine.

The Paris-based company said on Monday that the tie-up would strictly focus its attention on developing small molecule-based immune-oncology treatments that could be given to fight both blood cancer and solid tumors.

The collaboration includes major research and development efforts to advance a first-in-class small molecule approach to treat solid and haematopoietic cancers by enhancing the anti-tumor activity of human lymphocytes.

Regeneron and Sanofi collaborate to make new antibody Cancer treatments in Immuno-oncology

Regeneron and Sanofi collaborate to make new antibody Cancer treatments

Regeneron Pharmaceuticals and Sanofi have joined hands to work on a project in which they will discover, develop and commercialize new antibody cancer treatments in the field of immune-oncology. As a part of the project, the companies will develop a programmed cell death protein 1 (PD-1) inhibitor.

The inhibitor is in phase 1 state and its clinical trials will start in 2016. George D. Yancopoulos from Regeneron was of the view, "The field of immuno-oncology has shown the potential to dramatically improve outcomes for patients with certain types of cancer. However, the field is still in its very early days".

FDA’s Advisory committee approves cholesterol-lowering drug Praluent Tuesday

FDA’s Advisory committee approves cholesterol-lowering drug Praluent Tuesday

An advisory committee of the US Food and Drug Administration (FDA) has approved a new type of cholesterol-lowering drug Praluent Tuesday.

The drug made by Sanofi SA and Regeneron Pharmaceuticals just got recommended 13 to 3 for approval by a panel. Praluent is a new class of LDL-lowering drugs that inhibits a protein known as PCSK9.

Although the drug has been approved, many panelists agree that the drug should be given to patients with a genetic disorder called familial hypercholesterolemia, or FH, who have very high cholesterol levels and a heightened risk of heart attacks and strokes at a young age.

The opinion of the panelists differed for larger groups of patients. They said they initially want to use of the product limited.

FDA to speed up review of Fabry Therapy, says Genzyme

FDA to speed up review of Fabry Therapy, says Genzyme

Genzyme, a Sanofi company, said on Tuesday that the United States Food and Drug Administration (FDA) has agreed to speed up review for the development of GZ/SAR402671. Sanofi’s GZ/SAR402671 is a new investigational oral substrate reduction therapy, which can treat Fabry disease.

Fabry disease is an inherited, potentially fatal disorder, which is characterized by the buildup of a particular type of fat. That fat can results in cell damage, which could lead to pain, kidney failure, hearing loss, stroke and heart attack.



Check out More news from Telecom Sector :: Pharmaceutical Sector :: Auto Sector :: Infrastructure :: Real Estate


Syndicate content